EPIVIR Drug Patent Profile

Which patents cover Epivir, and when can generic versions of Epivir launch?

Epivir is a drug marketed by Viiv Hlthcare and Glaxosmithkline and is included in four NDAs.

The generic ingredient in EPIVIR is lamivudine. There are twenty-nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the lamivudine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Epivir

A generic version of EPIVIR was approved as lamivudine by APOTEX on December 2^nd, 2011.

Summary for EPIVIR

US Patents:	0
Applicants:	2
NDAs:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	46
Patent Applications:	4,094
Drug Prices:	Drug price information for EPIVIR
What excipients (inactive ingredients) are in EPIVIR?	EPIVIR excipients list
DailyMed Link:	EPIVIR at DailyMed

See drug prices for EPIVIR

Recent Clinical Trials for EPIVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Roswell Park Cancer Institute	Phase 2
Bess Frost, PhD	Phase 1/Phase 2
Owens Medical Research Foundation	Phase 1/Phase 2

See all EPIVIR clinical trials

Pharmacology for EPIVIR

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

US Patents and Regulatory Information for EPIVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	EPIVIR	lamivudine	SOLUTION;ORAL	020596-001	Nov 17, 1995	AA	RX	Yes	Yes
Glaxosmithkline	EPIVIR-HBV	lamivudine	SOLUTION;ORAL	021004-001	Dec 8, 1998		DISCN	Yes	No
Viiv Hlthcare	EPIVIR	lamivudine	TABLET;ORAL	020564-001	Nov 17, 1995	AB	RX	Yes	No
Viiv Hlthcare	EPIVIR	lamivudine	TABLET;ORAL	020564-003	Jun 24, 2002	AB	RX	Yes	Yes
Glaxosmithkline	EPIVIR-HBV	lamivudine	TABLET;ORAL	021003-001	Dec 8, 1998		DISCN	Yes	No

EU/EMA Drug Approvals for EPIVIR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva B.V.	Lamivudine Teva Pharma B.V.	lamivudine	EMEA/H/C/001111Lamivudine Teva Pharma B.V. is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children.	Authorised	yes	no	no	2009-12-10
Teva B.V.	Lamivudine Teva	lamivudine	EMEA/H/C/001113Lamivudine Teva is indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see in section 5.1).	Authorised	yes	no	no	2009-10-23
GlaxoSmithKline (Ireland) Limited	Zeffix	lamivudine	EMEA/H/C/000242Zeffix is indicated for the treatment of chronic hepatitis B in adults with:, , , compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate;, decompensated liver disease in combination with a second agent without cross-resistance to lamivudine., ,	Authorised	no	no	no	1999-07-29
ViiV Healthcare BV	Epivir	lamivudine	EMEA/H/C/000107Epivir is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children.,	Authorised	no	no	no	1996-08-08

International Patents for EPIVIR

See the table below for patents covering EPIVIR around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0711771	1,3-Oxathiolanes substitués ayant des propriétés antivirales (Substituted-1,3-oxathiolanes with antiviral properties)
Tunisia	SN91029	LES ANALOGUES DU NUCLEOSIDE DE 1,3-OXATHIOLANE
Denmark	0517145
Ireland	891136
Croatia	P940041	1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES

Supplementary Protection Certificates for EPIVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0382526	C960025	Netherlands		PRODUCT NAME: LAMIVUDINUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/015/001 - EU/1/96/015/002 19960808
0513917	C980018	Netherlands		PRODUCT NAME: LAMIVUDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001-002 19980318
2924034	LUC00114	Luxembourg		PRODUCT NAME: DORAVIRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI EN COMBINAISON AVEC LA LAMIVUDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI EN COMBINAISON AVEC DU TENOFOVIR OU UN DE SES ESTERS, EN PARTICULIER UN ESTER DE DISOPROXIL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER UN SEL DE FUMARATE; AUTHORISATION NUMBER AND DATE: EU/1/18/1333 20181126
0382526	SPC/GB96/043	United Kingdom		PRODUCT NAME: LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: CH 53662 19960228; CH 53663 19960228; UK EU/1/96/015/001 19960808; UK EU/1/96/015/002 19960808
0382526	19675032	Germany		PRODUCT NAME: LAMIVUDINE, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH GEEIGNETEN SALZES; NAT. REGISTRATION NO/DATE: EU/1/96/015/001-002 19960808 FIRST REGISTRATION: CH 53662 53663 19960228

EPIVIR (lamivudine): Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

EPIVIR (lamivudine) is a long-established oral antiviral in HIV therapy. Its market has been shaped by (1) patent and exclusivity milestones that opened generic competition, (2) guideline-driven shifts in preferred first-line regimens toward fixed-dose combinations and newer agents, and (3) durability of demand as an HIV backbone drug in both adult and pediatric use.

How did EPIVIR’s market structure evolve from originator to generics?

Patent and exclusivity-driven market opening

EPIVIR entered commercial maturity in the 1990s and early 2000s, then faced accelerating erosion as generic lamivudine launched globally. The key dynamic is that lamivudine’s patent wall does not define demand after generic entry; instead, usage persists where clinicians keep lamivudine-based combinations in place.

Key outcomes for market structure:

• Generic substitution reduced unit pricing and shifted competition to lowest-cost supply.
• Formulation and packaging (tablets and solution for pediatric dosing) sustained differentiated demand even when pricing compressed.
• Multiple indications’ overlap mattered for procurement volumes, since lamivudine appears across HIV and HBV treatment pathways.

Competitive intensity: why price compression is persistent

Lamivudine is mature and widely manufactured. Post-generic entry, competitive pressure does not fade; it cycles with procurement behavior:

• Tender-based purchasing drives near-term volume allocation to lowest compliant suppliers.
• Contracting with distributors and government formularies favors consistent supply rather than clinical differentiation.
• Brand value does not translate into premium pricing once generics are entrenched.

What demand channels kept EPIVIR relevant after generic erosion?

HIV regimen placement and switching behavior

EPIVIR’s survival in practice comes from its role as an antiviral backbone component. HIV treatment guidelines can evolve, but regimen switching does not eliminate demand overnight because:

• Patients already stable on lamivudine-containing combinations often continue unless virologic failure, resistance, or tolerability issues arise.
• Fixed-dose combinations that include lamivudine compete on convenience, not on complete clinical replacement of lamivudine across all patient segments.

Pediatric dosing and formulation utility

Lamivudine’s availability in dosing formats that support pediatric titration supports continued utilization even as adult regimen preferences shift:

• Pediatric providers often prioritize established agents with dosing familiarity and reliable supply.
• Pharmacies and clinics maintain stable ordering patterns for child-appropriate strengths and formulations.

HBV linkage: additional volume base

Lamivudine is used for chronic hepatitis B in multiple countries. That creates an additional demand sink that can partly cushion HIV-only demand volatility:

• HBV treatment flows can offset HIV procurement slowdowns, depending on local guideline interpretation and reimbursement rules.

What financial trajectory did EPIVIR follow over the product life cycle?

From branded growth to decline after generic entry

The financial trajectory for EPIVIR aligns with a classic originator pattern in mature antivirals:

1. Branded adoption and volume build in early years of widespread HIV combination therapy.
2. Peak revenue period before the bulk of global generic entry.
3. Revenue compression after loss of exclusivity, with brand-to-generic substitution driving a steep fall in unit economics.
4. Stabilization at low pricing levels where “market presence” continues via generic supply, not via EPIVIR-branded performance.

How to read “financial trajectory” in a generic era

Once generic lamivudine saturates the market:

• “EPIVIR revenue” becomes less meaningful than market value share and remaining brand stickiness.
• Investors track broader “lamivudine” categories rather than the brand line item.
• Financial performance becomes supplier-driven: procurement wins, tender renewals, and supply reliability matter more than promotional or incremental clinical differentiation.

Pricing dynamics: erosion is structurally linked to procurement

Lamivudine pricing is governed by procurement economics:

• As more suppliers enter, price bottoms out under competitive tender pressure.
• The product’s mature status reduces willingness to pay for branded versions.
• Financial outcomes track contract awards, not brand strength.

What market forces most affected EPIVIR’s revenue sensitivity?

Guideline shifts toward newer regimens

Even without immediate discontinuation of lamivudine, shifting guideline preferences reduce incremental prescribing:

• Clinicians prefer regimens with improved resistance profiles and more favorable long-term outcomes.
• Fixed-dose combinations can displace component prescribing, reducing incremental demand for standalone lamivudine.

Resistance and regimen durability

Lamivudine resistance affects clinical choices over time:

• Resistance patterns influence whether clinicians keep lamivudine in first-line options.
• Post-initiation switching depends on resistance history and prior drug exposure.

Supply and compliance constraints

Generic-market performance depends on quality systems and regulatory continuity:

• Manufacturing disruptions or compliance issues can temporarily pull supply, affecting contract allocations.
• Stable quality systems support continued tender wins and volume capture.

How does EPIVIR compare economically to newer HIV backbones?

Competitive positioning is “cost and familiarity,” not innovation

Newer HIV backbones usually compete on:

• improved resistance barriers,
• simplified dosing regimens,
• broader “preferred list” status in guidelines.

EPIVIR’s economic positioning in later years is:

• low cost after generic entry,
• proven dosing familiarity,
• continued use in existing patients and in settings where formularies maintain lamivudine-containing options.

Category view: lamivudine’s market stays, branded premium doesn’t

In investment terms:

• “Market size” for lamivudine can remain stable or decline slowly.
• “Brand value” generally collapses after exclusivity, replaced by commoditized supply economics.

Where do the biggest market swings come from?

Tender cycles and reimbursement rule changes

For mature antivirals, the dominant short-cycle drivers are administrative:

• government formulary updates,
• reimbursement changes,
• tender cycle timing and awarded contract duration.

Public health procurement volatility

Procurement volumes can shift when:

• national programs reorder due to stock management,
• budget allocations change,
• donor funding or procurement pooling policies adjust.

What is the net impact on EPIVIR’s financial trajectory?

Bottom line

EPIVIR’s financial path is a decline-and-stabilize pattern:

• Branded revenue declines sharply after generic entry and exclusivity loss.
• Commercial relevance persists through continued generic supply and ongoing HIV treatment use.
• Upside is limited because lamivudine is not a new innovation engine; it is a mature backbone whose economics are driven by low-cost competition.

Practical investor framing

• Treat EPIVIR as a mature, commoditized antiviral where earnings power depends on supply chain execution and contract wins rather than premium pricing.
• For market growth, track lamivudine category volumes and HBV-related demand rather than EPIVIR-branded growth expectations.

Key Takeaways

• EPIVIR’s market evolution is dominated by loss of exclusivity and generic substitution, causing sustained price compression.
• Demand persists due to HIV regimen backbone use, pediatric dosing utility, and HBV-linked utilization.
• EPIVIR’s financial trajectory follows a branded decline after generic entry with stabilization driven by tender-based procurement and stable category demand.
• Future upside is constrained; value creation shifts to supplier execution and contract capture, not innovation-led premium pricing.

FAQs

1) What drives EPIVIR sales in a generic-dominated market?

Procurement decisions tied to tenders, formulary inclusion, supply reliability, and continued clinical use in established patients.

2) Does EPIVIR benefit from HBV demand or is it HIV-only?

Lamivudine is used in HBV as well, which can add volume alongside HIV demand depending on country-specific guidelines and reimbursement.

3) Why do guideline updates not eliminate lamivudine demand quickly?

Patients on stable regimens often remain on current therapies unless resistance, tolerability, or virologic failure forces change.

4) What is the biggest financial risk for EPIVIR economics?

Sustained price erosion from generic competition, amplified by tender-driven contracting that rewards the lowest compliant supplier.

5) How should investors think about “EPIVIR” versus “lamivudine category” value?

EPIVIR-branded value typically collapses post-exclusivity; the economically meaningful view becomes the broader lamivudine category and who wins supply contracts.

---

References

[1] FDA. (n.d.). EPIVIR (lamivudine) prescribing information. U.S. Food and Drug Administration.
[2] European Medicines Agency. (n.d.). EPIVIR: EPAR product information. European Medicines Agency.
[3] World Health Organization. (n.d.). Guidelines for antiretroviral therapy and hepatitis B management (lamivudine-containing regimens context). World Health Organization.
[4] NIH (U.S. National Library of Medicine). (n.d.). Clinical trial and drug monograph records for lamivudine (EPIVIR). National Institutes of Health.